Ultra-early treatment of bone marrow-derived mesenchymal stem cells for focal cerebral ischemia/reperfusion injury

摘要

The time point at which bone marrow-derived mesenchymal stem cells (BMSCs) can be used in transplantation for the treatment of ischemic brain injury remains unclear. In the present study, BMSCs were transplanted to the ischemic site 90 minutes post-ischemia. The results demonstrated that the transplanted BMSCs improved neurological function, reduced infarct volume, increased survivin expression, decreased caspase-3 expression and reduced apoptosis. This suggests that BMSCs transplanted at an ultra-early stage ameliorated brain ischemia by increasing survivin expression, decreasing caspase-3 expression and reducing apoptosis at the ischemia/reperfusion injury site.